Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): PMS-Rivastigmine (02306034), PMS-Rivastigmine (02306050), Rivastigmine Patch 5 (02479540), Exelon Patch 15 (02432803), Rivastigmine Patch 15 (02479567), Rivastigmine Patch 10 (02479559). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.
RIVASTIGMINE
Form:
24 of 24 products shown
20 Limited Use · 4 not a benefit
Other products in the same Health Canada class (N06DA) — coverage varies; not interchangeable
Donepezil (Aricept RDT): limited Use 347, 348, Not a benefit
Galantamine (Reminyl ER): limited Use 347, 348, Not a benefit
Apo-Rivastigmine · DIN 02336715 · 1.5mg · capsule
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 347, 348 required
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Rivastigmine · DIN 02336715
Manufacturer: Apotex Inc.; listing date 2010-03-02
Health Canada: Marketed since 2010-04-07 · brand APO-RIVASTIGMINE · ATC N06DA03 RIVASTIGMINE · form Capsule · route Oral · ingredients RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) 1.5 MG · company Apotex inc · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82234 · Verify on the e-Formulary ↗ (DIN 02336715)
Source record
DIN 02336715: Apo-Rivastigmine
Raw flags: sec12=Y, sec3=Y
Item: 120400019; group id 197; item number 0362; lccId 00028; manufacturer id APX
Source form: Cap; strength: 1.5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.6515; ministry $0.6514
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02336715
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82234Interchangeable products
Exelon · DIN 02242115 · $0.6514
Jamp Rivastigmine · DIN 02485362 · $0.6514
Jamp Rivastigmine Capsules · DIN 02552256 · $0.6514
Med-Rivastigmine · DIN 02401614 · $0.6514
Mint-Rivastigmine · DIN 02406985 · $0.6514
Sandoz Rivastigmine · DIN 02324563 · $0.6514
Shortage status: resolved shortage (ended 2025-07-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02336715
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Exelon · DIN 02242115 · 1.5mg · capsule
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 347, 348 required
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Exelon · DIN 02242115
Manufacturer: Knight Therapeutics Inc.; listing date 2001-03-07
Health Canada: Marketed since 2022-11-24 · brand EXELON · ATC N06DA03 RIVASTIGMINE · form Capsule · route Oral · ingredients RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) 1.5 MG · company Knight therapeutics inc. · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65791 · Verify on the e-Formulary ↗ (DIN 02242115)
Source record
DIN 02242115: Exelon
Raw flags: sec12=Y, sec3=Y
Item: 120400019; group id 197; item number 0362; lccId 00028; manufacturer id KNT
Source form: Cap; strength: 1.5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $3.3711; ministry $0.6514
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02242115
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65791Interchangeable products
Apo-Rivastigmine · DIN 02336715 · $0.6514
Jamp Rivastigmine · DIN 02485362 · $0.6514
Jamp Rivastigmine Capsules · DIN 02552256 · $0.6514
Med-Rivastigmine · DIN 02401614 · $0.6514
Mint-Rivastigmine · DIN 02406985 · $0.6514
Sandoz Rivastigmine · DIN 02324563 · $0.6514
Shortage status: resolved shortage (ended 2025-12-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02242115
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Rivastigmine · DIN 02485362 · 1.5mg · capsule
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 347, 348 required
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Rivastigmine · DIN 02485362
Manufacturer: Jamp Pharma Corporation; listing date 2020-01-31
Health Canada: Marketed since 2020-02-10 · brand JAMP RIVASTIGMINE · ATC N06DA03 RIVASTIGMINE · form Capsule · route Oral · ingredients RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) 1.5 MG · company Jamp pharma corporation · schedule Prescription
Jamp Rivastigmine: Formulary list price $0.6514/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6514 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97561 · Verify on the e-Formulary ↗ (DIN 02485362)
Source record
DIN 02485362: Jamp Rivastigmine
Raw flags: sec12=Y, sec3=Y
Item: 120400019; group id 197; item number 0362; lccId 00028; manufacturer id JPC
Source form: Cap; strength: 1.5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.6514; ministry $0.6514
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02485362
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97561Interchangeable products
Apo-Rivastigmine · DIN 02336715 · $0.6514
Exelon · DIN 02242115 · $0.6514
Jamp Rivastigmine Capsules · DIN 02552256 · $0.6514
Med-Rivastigmine · DIN 02401614 · $0.6514
Mint-Rivastigmine · DIN 02406985 · $0.6514
Sandoz Rivastigmine · DIN 02324563 · $0.6514
Shortage status: resolved shortage (ended 2025-08-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02485362
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Rivastigmine Capsules · DIN 02552256 · 1.5mg · capsule
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 347, 348 required
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Rivastigmine Capsules · DIN 02552256
Manufacturer: Jamp Pharma Corporation; listing date 2025-08-29
Health Canada: Marketed since 2025-07-11 · brand JAMP RIVASTIGMINE CAPSULES · ATC N06DA03 RIVASTIGMINE · form Capsule · route Oral · ingredients RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) 1.5 MG · company Jamp pharma corporation · schedule Prescription
Jamp Rivastigmine Capsules: Formulary list price $0.6514/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6514 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104093 · Verify on the e-Formulary ↗ (DIN 02552256)
Source record
DIN 02552256: Jamp Rivastigmine Capsules
Raw flags: sec12=Y, sec3=Y
Item: 120400019; group id 197; item number 0362; lccId 00028; manufacturer id JPC
Source form: Cap; strength: 1.5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.6514; ministry $0.6514
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02552256
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104093Interchangeable products
Apo-Rivastigmine · DIN 02336715 · $0.6514
Exelon · DIN 02242115 · $0.6514
Jamp Rivastigmine · DIN 02485362 · $0.6514
Med-Rivastigmine · DIN 02401614 · $0.6514
Mint-Rivastigmine · DIN 02406985 · $0.6514
Sandoz Rivastigmine · DIN 02324563 · $0.6514
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02552256
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Med-Rivastigmine · DIN 02401614 · 1.5mg · capsule
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 347, 348 required
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Med-Rivastigmine · DIN 02401614
Manufacturer: Generic Medical Partners Inc.; listing date 2014-01-30
Health Canada: Marketed since 2013-11-27 · brand MED-RIVASTIGMINE · ATC N06DA03 RIVASTIGMINE · form Capsule · route Oral · ingredients RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) 1.5 MG · company Generic medical partners inc · schedule Prescription
Med-Rivastigmine: Formulary list price $0.6514/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6514 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88650 · Verify on the e-Formulary ↗ (DIN 02401614)
Source record
DIN 02401614: Med-Rivastigmine
Raw flags: sec12=Y, sec3=Y
Item: 120400019; group id 197; item number 0362; lccId 00028; manufacturer id GMP
Source form: Cap; strength: 1.5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.6514; ministry $0.6514
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02401614
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88650Interchangeable products
Apo-Rivastigmine · DIN 02336715 · $0.6514
Exelon · DIN 02242115 · $0.6514
Jamp Rivastigmine · DIN 02485362 · $0.6514
Jamp Rivastigmine Capsules · DIN 02552256 · $0.6514
Mint-Rivastigmine · DIN 02406985 · $0.6514
Sandoz Rivastigmine · DIN 02324563 · $0.6514
Shortage status: shortage reported ended 2026-08-17 (report last updated 2026-08-17); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02401614
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Rivastigmine · DIN 02336723 · 3mg · capsule
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 347, 348 required
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Rivastigmine · DIN 02336723
Manufacturer: Apotex Inc.; listing date 2010-03-02
Health Canada: Marketed since 2010-04-07 · brand APO-RIVASTIGMINE · ATC N06DA03 RIVASTIGMINE · form Capsule · route Oral · ingredients RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) 3 MG · company Apotex inc · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82235 · Verify on the e-Formulary ↗ (DIN 02336723)
Source record
DIN 02336723: Apo-Rivastigmine
Raw flags: sec12=Y, sec3=Y
Item: 120400020; group id 197; item number 0363; lccId 00028; manufacturer id APX
Source form: Cap; strength: 3mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.6515; ministry $0.6514
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02336723
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82235Interchangeable products
Exelon · DIN 02242116 · $0.6514
Jamp Rivastigmine · DIN 02485370 · $0.6514
Jamp Rivastigmine Capsules · DIN 02552264 · $0.6514
Med-Rivastigmine · DIN 02401622 · $0.6514
Mint-Rivastigmine · DIN 02406993 · $0.6514
Sandoz Rivastigmine · DIN 02324571 · $0.6514
Shortage status: resolved shortage (ended 2025-07-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02336723
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Exelon · DIN 02242116 · 3mg · capsule
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 347, 348 required
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Exelon · DIN 02242116
Manufacturer: Knight Therapeutics Inc.; listing date 2001-03-07
Health Canada: Marketed since 2022-12-09 · brand EXELON · ATC N06DA03 RIVASTIGMINE · form Capsule · route Oral · ingredients RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) 3 MG · company Knight therapeutics inc. · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65792 · Verify on the e-Formulary ↗ (DIN 02242116)
Source record
DIN 02242116: Exelon
Raw flags: sec12=Y, sec3=Y
Item: 120400020; group id 197; item number 0363; lccId 00028; manufacturer id KNT
Source form: Cap; strength: 3mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $3.3711; ministry $0.6514
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02242116
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65792Interchangeable products
Apo-Rivastigmine · DIN 02336723 · $0.6514
Jamp Rivastigmine · DIN 02485370 · $0.6514
Jamp Rivastigmine Capsules · DIN 02552264 · $0.6514
Med-Rivastigmine · DIN 02401622 · $0.6514
Mint-Rivastigmine · DIN 02406993 · $0.6514
Sandoz Rivastigmine · DIN 02324571 · $0.6514
Shortage status: resolved shortage (ended 2025-11-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02242116
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Rivastigmine · DIN 02485370 · 3mg · capsule
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 347, 348 required
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Rivastigmine · DIN 02485370
Manufacturer: Jamp Pharma Corporation; listing date 2020-01-31
Health Canada: Marketed since 2020-02-10 · brand JAMP RIVASTIGMINE · ATC N06DA03 RIVASTIGMINE · form Capsule · route Oral · ingredients RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) 3 MG · company Jamp pharma corporation · schedule Prescription
Jamp Rivastigmine: Formulary list price $0.6514/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6514 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97562 · Verify on the e-Formulary ↗ (DIN 02485370)
Source record
DIN 02485370: Jamp Rivastigmine
Raw flags: sec12=Y, sec3=Y
Item: 120400020; group id 197; item number 0363; lccId 00028; manufacturer id JPC
Source form: Cap; strength: 3mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.6514; ministry $0.6514
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02485370
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97562Interchangeable products
Apo-Rivastigmine · DIN 02336723 · $0.6514
Exelon · DIN 02242116 · $0.6514
Jamp Rivastigmine Capsules · DIN 02552264 · $0.6514
Med-Rivastigmine · DIN 02401622 · $0.6514
Mint-Rivastigmine · DIN 02406993 · $0.6514
Sandoz Rivastigmine · DIN 02324571 · $0.6514
Shortage status: resolved shortage (ended 2025-08-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02485370
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Rivastigmine Capsules · DIN 02552264 · 3mg · capsule
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 347, 348 required
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Rivastigmine Capsules · DIN 02552264
Manufacturer: Jamp Pharma Corporation; listing date 2025-08-29
Health Canada: Marketed since 2025-07-11 · brand JAMP RIVASTIGMINE CAPSULES · ATC N06DA03 RIVASTIGMINE · form Capsule · route Oral · ingredients RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) 3 MG · company Jamp pharma corporation · schedule Prescription
Jamp Rivastigmine Capsules: Formulary list price $0.6514/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6514 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104094 · Verify on the e-Formulary ↗ (DIN 02552264)
Source record
DIN 02552264: Jamp Rivastigmine Capsules
Raw flags: sec12=Y, sec3=Y
Item: 120400020; group id 197; item number 0363; lccId 00028; manufacturer id JPC
Source form: Cap; strength: 3mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.6514; ministry $0.6514
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02552264
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104094Interchangeable products
Apo-Rivastigmine · DIN 02336723 · $0.6514
Exelon · DIN 02242116 · $0.6514
Jamp Rivastigmine · DIN 02485370 · $0.6514
Med-Rivastigmine · DIN 02401622 · $0.6514
Mint-Rivastigmine · DIN 02406993 · $0.6514
Sandoz Rivastigmine · DIN 02324571 · $0.6514
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02552264
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Med-Rivastigmine · DIN 02401622 · 3mg · capsule
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 347, 348 required
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Med-Rivastigmine · DIN 02401622
Manufacturer: Generic Medical Partners Inc.; listing date 2014-01-30
Health Canada: Marketed since 2013-11-27 · brand MED-RIVASTIGMINE · ATC N06DA03 RIVASTIGMINE · form Capsule · route Oral · ingredients RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) 3 MG · company Generic medical partners inc · schedule Prescription
Med-Rivastigmine: Formulary list price $0.6514/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6514 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88651 · Verify on the e-Formulary ↗ (DIN 02401622)
Source record
DIN 02401622: Med-Rivastigmine
Raw flags: sec12=Y, sec3=Y
Item: 120400020; group id 197; item number 0363; lccId 00028; manufacturer id GMP
Source form: Cap; strength: 3mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.6514; ministry $0.6514
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02401622
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88651Interchangeable products
Apo-Rivastigmine · DIN 02336723 · $0.6514
Exelon · DIN 02242116 · $0.6514
Jamp Rivastigmine · DIN 02485370 · $0.6514
Jamp Rivastigmine Capsules · DIN 02552264 · $0.6514
Mint-Rivastigmine · DIN 02406993 · $0.6514
Sandoz Rivastigmine · DIN 02324571 · $0.6514
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02401622
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Rivastigmine · DIN 02336731 · 4.5mg · capsule
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 347, 348 required
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Rivastigmine · DIN 02336731
Manufacturer: Apotex Inc.; listing date 2010-03-02
Health Canada: Marketed since 2010-04-07 · brand APO-RIVASTIGMINE · ATC N06DA03 RIVASTIGMINE · form Capsule · route Oral · ingredients RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) 4.5 MG · company Apotex inc · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82236 · Verify on the e-Formulary ↗ (DIN 02336731)
Source record
DIN 02336731: Apo-Rivastigmine
Raw flags: sec12=Y, sec3=Y
Item: 120400021; group id 197; item number 0364; lccId 00028; manufacturer id APX
Source form: Cap; strength: 4.5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.6515; ministry $0.6514
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02336731
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82236Interchangeable products
Exelon · DIN 02242117 · $0.6514
Jamp Rivastigmine · DIN 02485389 · $0.6514
Jamp Rivastigmine Capsules · DIN 02552272 · $0.6514
Med-Rivastigmine · DIN 02401630 · $0.6514
Mint-Rivastigmine · DIN 02407000 · $0.6514
Sandoz Rivastigmine · DIN 02324598 · $0.6514
Shortage status: resolved shortage (ended 2025-07-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02336731
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Exelon · DIN 02242117 · 4.5mg · capsule
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 347, 348 required
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Exelon · DIN 02242117
Manufacturer: Knight Therapeutics Inc.; listing date 2001-03-07
Health Canada: Marketed since 2022-11-17 · brand EXELON · ATC N06DA03 RIVASTIGMINE · form Capsule · route Oral · ingredients RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) 4.5 MG · company Knight therapeutics inc. · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65793 · Verify on the e-Formulary ↗ (DIN 02242117)
Source record
DIN 02242117: Exelon
Raw flags: sec12=Y, sec3=Y
Item: 120400021; group id 197; item number 0364; lccId 00028; manufacturer id KNT
Source form: Cap; strength: 4.5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $3.3711; ministry $0.6514
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02242117
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65793Interchangeable products
Apo-Rivastigmine · DIN 02336731 · $0.6514
Jamp Rivastigmine · DIN 02485389 · $0.6514
Jamp Rivastigmine Capsules · DIN 02552272 · $0.6514
Med-Rivastigmine · DIN 02401630 · $0.6514
Mint-Rivastigmine · DIN 02407000 · $0.6514
Sandoz Rivastigmine · DIN 02324598 · $0.6514
Shortage status: resolved shortage (ended 2025-11-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02242117
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Rivastigmine · DIN 02485389 · 4.5mg · capsule
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 347, 348 required
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Rivastigmine · DIN 02485389
Manufacturer: Jamp Pharma Corporation; listing date 2020-01-31
Health Canada: Marketed since 2020-02-10 · brand JAMP RIVASTIGMINE · ATC N06DA03 RIVASTIGMINE · form Capsule · route Oral · ingredients RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) 4.5 MG · company Jamp pharma corporation · schedule Prescription
Jamp Rivastigmine: Formulary list price $0.6514/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6514 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97563 · Verify on the e-Formulary ↗ (DIN 02485389)
Source record
DIN 02485389: Jamp Rivastigmine
Raw flags: sec12=Y, sec3=Y
Item: 120400021; group id 197; item number 0364; lccId 00028; manufacturer id JPC
Source form: Cap; strength: 4.5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.6514; ministry $0.6514
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02485389
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97563Interchangeable products
Apo-Rivastigmine · DIN 02336731 · $0.6514
Exelon · DIN 02242117 · $0.6514
Jamp Rivastigmine Capsules · DIN 02552272 · $0.6514
Med-Rivastigmine · DIN 02401630 · $0.6514
Mint-Rivastigmine · DIN 02407000 · $0.6514
Sandoz Rivastigmine · DIN 02324598 · $0.6514
Shortage status: resolved shortage (ended 2025-08-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02485389
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Rivastigmine Capsules · DIN 02552272 · 4.5mg · capsule
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 347, 348 required
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Rivastigmine Capsules · DIN 02552272
Manufacturer: Jamp Pharma Corporation; listing date 2025-08-29
Health Canada: Marketed since 2025-07-11 · brand JAMP RIVASTIGMINE CAPSULES · ATC N06DA03 RIVASTIGMINE · form Capsule · route Oral · ingredients RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) 4.5 MG · company Jamp pharma corporation · schedule Prescription
Jamp Rivastigmine Capsules: Formulary list price $0.6514/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6514 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104095 · Verify on the e-Formulary ↗ (DIN 02552272)
Source record
DIN 02552272: Jamp Rivastigmine Capsules
Raw flags: sec12=Y, sec3=Y
Item: 120400021; group id 197; item number 0364; lccId 00028; manufacturer id JPC
Source form: Cap; strength: 4.5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.6514; ministry $0.6514
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02552272
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104095Interchangeable products
Apo-Rivastigmine · DIN 02336731 · $0.6514
Exelon · DIN 02242117 · $0.6514
Jamp Rivastigmine · DIN 02485389 · $0.6514
Med-Rivastigmine · DIN 02401630 · $0.6514
Mint-Rivastigmine · DIN 02407000 · $0.6514
Sandoz Rivastigmine · DIN 02324598 · $0.6514
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02552272
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Med-Rivastigmine · DIN 02401630 · 4.5mg · capsule
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 347, 348 required
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Med-Rivastigmine · DIN 02401630
Manufacturer: Generic Medical Partners Inc.; listing date 2014-01-30
Health Canada: Marketed since 2014-11-12 · brand MED-RIVASTIGMINE · ATC N06DA03 RIVASTIGMINE · form Capsule · route Oral · ingredients RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) 4.5 MG · company Generic medical partners inc · schedule Prescription
Med-Rivastigmine: Formulary list price $0.6514/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6514 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88652 · Verify on the e-Formulary ↗ (DIN 02401630)
Source record
DIN 02401630: Med-Rivastigmine
Raw flags: sec12=Y, sec3=Y
Item: 120400021; group id 197; item number 0364; lccId 00028; manufacturer id GMP
Source form: Cap; strength: 4.5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.6514; ministry $0.6514
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02401630
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88652Interchangeable products
Apo-Rivastigmine · DIN 02336731 · $0.6514
Exelon · DIN 02242117 · $0.6514
Jamp Rivastigmine · DIN 02485389 · $0.6514
Jamp Rivastigmine Capsules · DIN 02552272 · $0.6514
Mint-Rivastigmine · DIN 02407000 · $0.6514
Sandoz Rivastigmine · DIN 02324598 · $0.6514
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02401630
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Rivastigmine · DIN 02336758 · 6mg · capsule
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 347, 348 required
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Rivastigmine · DIN 02336758
Manufacturer: Apotex Inc.; listing date 2010-03-02
Health Canada: Marketed since 2010-04-07 · brand APO-RIVASTIGMINE · ATC N06DA03 RIVASTIGMINE · form Capsule · route Oral · ingredients RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) 6 MG · company Apotex inc · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82237 · Verify on the e-Formulary ↗ (DIN 02336758)
Source record
DIN 02336758: Apo-Rivastigmine
Raw flags: sec12=Y, sec3=Y
Item: 120400022; group id 197; item number 0365; lccId 00028; manufacturer id APX
Source form: Cap; strength: 6mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.6515; ministry $0.6514
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02336758
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82237Interchangeable products
Exelon · DIN 02242118 · $0.6514
Jamp Rivastigmine · DIN 02485397 · $0.6514
Jamp Rivastigmine Capsules · DIN 02552280 · $0.6514
Med-Rivastigmine · DIN 02401649 · $0.6514
Mint-Rivastigmine · DIN 02407019 · $0.6514
Sandoz Rivastigmine · DIN 02324601 · $0.6514
Shortage status: resolved shortage (ended 2025-07-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02336758
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Exelon · DIN 02242118 · 6mg · capsule
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 347, 348 required
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Exelon · DIN 02242118
Manufacturer: Knight Therapeutics Inc.; listing date 2001-03-07
Health Canada: Marketed since 2022-11-28 · brand EXELON · ATC N06DA03 RIVASTIGMINE · form Capsule · route Oral · ingredients RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) 6 MG · company Knight therapeutics inc. · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65794 · Verify on the e-Formulary ↗ (DIN 02242118)
Source record
DIN 02242118: Exelon
Raw flags: sec12=Y, sec3=Y
Item: 120400022; group id 197; item number 0365; lccId 00028; manufacturer id KNT
Source form: Cap; strength: 6mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $3.3711; ministry $0.6514
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02242118
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65794Interchangeable products
Apo-Rivastigmine · DIN 02336758 · $0.6514
Jamp Rivastigmine · DIN 02485397 · $0.6514
Jamp Rivastigmine Capsules · DIN 02552280 · $0.6514
Med-Rivastigmine · DIN 02401649 · $0.6514
Mint-Rivastigmine · DIN 02407019 · $0.6514
Sandoz Rivastigmine · DIN 02324601 · $0.6514
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02242118
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Rivastigmine · DIN 02485397 · 6mg · capsule
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 347, 348 required
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Rivastigmine · DIN 02485397
Manufacturer: Jamp Pharma Corporation; listing date 2020-01-31
Health Canada: Marketed since 2020-02-10 · brand JAMP RIVASTIGMINE · ATC N06DA03 RIVASTIGMINE · form Capsule · route Oral · ingredients RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) 6 MG · company Jamp pharma corporation · schedule Prescription
Jamp Rivastigmine: Formulary list price $0.6514/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6514 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97564 · Verify on the e-Formulary ↗ (DIN 02485397)
Source record
DIN 02485397: Jamp Rivastigmine
Raw flags: sec12=Y, sec3=Y
Item: 120400022; group id 197; item number 0365; lccId 00028; manufacturer id JPC
Source form: Cap; strength: 6mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.6514; ministry $0.6514
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02485397
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97564Interchangeable products
Apo-Rivastigmine · DIN 02336758 · $0.6514
Exelon · DIN 02242118 · $0.6514
Jamp Rivastigmine Capsules · DIN 02552280 · $0.6514
Med-Rivastigmine · DIN 02401649 · $0.6514
Mint-Rivastigmine · DIN 02407019 · $0.6514
Sandoz Rivastigmine · DIN 02324601 · $0.6514
Shortage status: resolved shortage (ended 2022-05-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02485397
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Rivastigmine Capsules · DIN 02552280 · 6mg · capsule
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 347, 348 required
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Rivastigmine Capsules · DIN 02552280
Manufacturer: Jamp Pharma Corporation; listing date 2025-08-29
Health Canada: Marketed since 2025-07-11 · brand JAMP RIVASTIGMINE CAPSULES · ATC N06DA03 RIVASTIGMINE · form Capsule · route Oral · ingredients RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) 6 MG · company Jamp pharma corporation · schedule Prescription
Jamp Rivastigmine Capsules: Formulary list price $0.6514/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6514 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104096 · Verify on the e-Formulary ↗ (DIN 02552280)
Source record
DIN 02552280: Jamp Rivastigmine Capsules
Raw flags: sec12=Y, sec3=Y
Item: 120400022; group id 197; item number 0365; lccId 00028; manufacturer id JPC
Source form: Cap; strength: 6mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.6514; ministry $0.6514
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02552280
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104096Interchangeable products
Apo-Rivastigmine · DIN 02336758 · $0.6514
Exelon · DIN 02242118 · $0.6514
Jamp Rivastigmine · DIN 02485397 · $0.6514
Med-Rivastigmine · DIN 02401649 · $0.6514
Mint-Rivastigmine · DIN 02407019 · $0.6514
Sandoz Rivastigmine · DIN 02324601 · $0.6514
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02552280
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Med-Rivastigmine · DIN 02401649 · 6mg · capsule
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 347, 348 required
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Med-Rivastigmine · DIN 02401649
Manufacturer: Generic Medical Partners Inc.; listing date 2014-01-30
Health Canada: Marketed since 2013-11-27 · brand MED-RIVASTIGMINE · ATC N06DA03 RIVASTIGMINE · form Capsule · route Oral · ingredients RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) 6 MG · company Generic medical partners inc · schedule Prescription
Med-Rivastigmine: Formulary list price $0.6514/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6514 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88653 · Verify on the e-Formulary ↗ (DIN 02401649)
Source record
DIN 02401649: Med-Rivastigmine
Raw flags: sec12=Y, sec3=Y
Item: 120400022; group id 197; item number 0365; lccId 00028; manufacturer id GMP
Source form: Cap; strength: 6mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.6514; ministry $0.6514
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02401649
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88653Interchangeable products
Apo-Rivastigmine · DIN 02336758 · $0.6514
Exelon · DIN 02242118 · $0.6514
Jamp Rivastigmine · DIN 02485397 · $0.6514
Jamp Rivastigmine Capsules · DIN 02552280 · $0.6514
Mint-Rivastigmine · DIN 02407019 · $0.6514
Sandoz Rivastigmine · DIN 02324601 · $0.6514
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02401649
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Exelon Patch 5 · DIN 02302845 · 9mg/5 Sq Cm · Trans Patch
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Exelon Patch 5 · DIN 02302845
Manufacturer: Knight Therapeutics Inc.; listing date 2017-01-31
Health Canada: Marketed since 2022-10-26 · brand EXELON PATCH 5 · ATC N06DA03 RIVASTIGMINE · form Patch · route Transdermal · ingredients RIVASTIGMINE 4.6 MG/24HOUR · company Knight therapeutics inc. · schedule Prescription
Exelon Patch 5: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78816 · Verify on the e-Formulary ↗ (DIN 02302845)
Source record
DIN 02302845: Exelon Patch 5
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 120400035; group id 198; item number 0366; lccId None; manufacturer id KNT
Source form: Trans Patch; strength: 9mg/5 Sq Cm
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02302845
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78816Interchangeable products
Mylan-Rivastigmine Patch 5 · DIN 02423413 · not recorded
Sandoz Rivastigmine Patch 5 · DIN 02426293 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02302845
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mylan-Rivastigmine Patch 5 · DIN 02423413 · 9mg/5 Sq Cm · Trans Patch
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mylan-Rivastigmine Patch 5 · DIN 02423413
Manufacturer: Mylan Pharmaceuticals ULC; listing date 2017-01-31
Health Canada: Marketed since 2016-12-05 · brand MYLAN-RIVASTIGMINE PATCH 5 · ATC N06DA03 RIVASTIGMINE · form Patch · route Transdermal · ingredients RIVASTIGMINE 4.6 MG/24HOUR · company Mylan pharmaceuticals ulc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90814 · Verify on the e-Formulary ↗ (DIN 02423413)
Source record
DIN 02423413: Mylan-Rivastigmine Patch 5
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 120400035; group id 198; item number 0366; lccId None; manufacturer id MYL
Source form: Trans Patch; strength: 9mg/5 Sq Cm
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $3.9773; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02423413
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90814Interchangeable products
Exelon Patch 5 · DIN 02302845 · not recorded
Sandoz Rivastigmine Patch 5 · DIN 02426293 · not recorded
Shortage status: resolved shortage (ended 2026-03-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02423413
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Rivastigmine Patch 5 · DIN 02426293 · 9mg/5 Sq Cm · Trans Patch
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandoz Rivastigmine Patch 5 · DIN 02426293
Manufacturer: Sandoz Canada Inc.; listing date 2017-01-31
Health Canada: Marketed since 2016-11-30 · brand SANDOZ RIVASTIGMINE PATCH 5 · ATC N06DA03 RIVASTIGMINE · form Patch · route Transdermal · ingredients RIVASTIGMINE 4.6 MG/24HOUR · company Sandoz canada incorporated · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91089 · Verify on the e-Formulary ↗ (DIN 02426293)
Source record
DIN 02426293: Sandoz Rivastigmine Patch 5
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 120400035; group id 198; item number 0366; lccId None; manufacturer id SDZ
Source form: Trans Patch; strength: 9mg/5 Sq Cm
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $3.9773; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02426293
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91089Interchangeable products
Exelon Patch 5 · DIN 02302845 · not recorded
Mylan-Rivastigmine Patch 5 · DIN 02423413 · not recorded
Shortage status: resolved shortage (ended 2024-12-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02426293
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Exelon Patch 10 · DIN 02302853 · 18mg/10 Sq Cm · Trans Patch
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Exelon Patch 10 · DIN 02302853
Manufacturer: Knight Therapeutics Inc.; listing date 2017-01-31
Health Canada: Marketed since 2022-11-10 · brand EXELON PATCH 10 · ATC N06DA03 RIVASTIGMINE · form Patch · route Transdermal · ingredients RIVASTIGMINE 9.5 MG/24HOUR · company Knight therapeutics inc. · schedule Prescription
Exelon Patch 10: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78817 · Verify on the e-Formulary ↗ (DIN 02302853)
Source record
DIN 02302853: Exelon Patch 10
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 120400036; group id 198; item number 0367; lccId None; manufacturer id KNT
Source form: Trans Patch; strength: 18mg/10 Sq Cm
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02302853
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78817Interchangeable products
Mylan-Rivastigmine Patch 10 · DIN 02423421 · not recorded
Sandoz Rivastigmine Patch 10 · DIN 02426307 · not recorded
Shortage status: resolved shortage (ended 2023-12-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02302853
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (12:04 Parasympathomimetic (Cholinergic) Agents) and how they are covered
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: BETHANECHOL CHLORIDE, CARBACHOL, PYRIDOSTIGMINE BROMIDE
12:04 Parasympathomimetic (Cholinergic) Agents
From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
No displayed matched alternative is a general benefit.
DONEPEZIL HCL · Off-Formulary Interchangeable, not an ODB benefit (6), Limited Use, codes 347, 348 (42)
1 INDICATIONS
ARICEPT (donepezil hydrochloride) is indicated for:
• symptomatic treatment of patients with mild, moderate and severe dementia of the Alzheimer’s
type.
PM: https://pdf.hres.ca/dpd_pm/00077966.PDF; date AUG 12, 1997; DIN 02232043; fetched 2026-09-10
Product monographGALANTAMINE HYDROBROMIDE · Listed, not a benefit (3), Limited Use, codes 347, 348 (15)
Indications
Galantamine ER (galantamine extended release capsules) is indicated for the symptomatic treatment of
patients with mild to moderate dementia of the Alzheimer’s type.
PM: https://pdf.hres.ca/dpd_pm/00085752.PDF; date 2026-08-11; DIN 02316943; fetched 2026-09-10
Product monograph
Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS
EXELON® (rivastigmine hydrogen tartrate) is indicated for:
• The symptomatic treatment of patients with mild to moderate dementia of the Alzheimer's
type.
• The symptomatic treatment of mild to moderate dementia in patients with idiopathic
Parkinson’s disease, with onset at least 2 years after the initial diagnosis of Parkinson’s
disease, and in whom other causes of dementia have been ruled out.
EXELON® has not been studied in controlled clinical trials for longer than 6 months.
EXELON® capsules and oral solution should only be prescribed by (or following consultation
with) clinicians who are experienced in the diagnosis and management of dementia.
1.1 Pediatrics
Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health
Canada has not authorized an indication for pediatric use.
1.2 Geriatrics
Geriatrics (≥ 65 years of age): Dose escalation in patients >85 years old should proceed with
caution. See 4.1 Dosing Considerations
https://pdf.hres.ca/dpd_pm/00085220.PDF
PM date: 2026-07-02
Source product: EXELON; DIN 02242115; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Med-Rivastigmine · DIN 02401614
Shortage status: shortage reported ended 2026-08-17 (report last updated 2026-08-17); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02401614
For Exelon Patch 5, Mylan-Rivastigmine Patch 5, Sandoz Rivastigmine Patch 5, Exelon Patch 10: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.